HMP Global October 18, 2024
Hannah Musick

AMCP Nexus 2024 session speakers Kelly K. Makay, RPh MBA, Senior Consultant, BluePeak Advisors, and Crescent Moore, PharmD, PhD, Director, Part D/Pharmacy, BluePeak Advisors, explored the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act, including the successes and challenges faced by stakeholders as they prepare for the changes ahead.

The Inflation Reduction Act of 2022, signed into law in August, includes provisions that will have a significant impact on Medicare, such as government authority to negotiate drug costs, changes to Medicare Part D benefits, and premium limitations. Additionally, the act enforces a maximum monthly cap on Part D cost-sharing.
“2025 is going to be one of the biggest years for the IRA because there is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Trends
Related Articles:
Private equity in health care: Fix the Medicare Physician Fee Schedule
Medicare $2,000 prescription drug cap starts Jan. 1
Redesigning Integrated Care For Dually Eligible People With Intellectual/Developmental Disabilities
CMS 2025 Physician Fee Schedule Includes 2.9 Percent Pay Cuts for Physicians
CMS Launches New Program for Mental Health, OUD Treatment

Share This Article